Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy Followed by Surgery and Radiation for Nasal and Paranasal Sinus Squamous Cell Carcinoma
NCT03493425Phase 2Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Mar 2019
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, Cisplatin micelle injection (HA132) and carboplatin in sinonasal squamous cell carcinoma (SNSCC) (2 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoints: Structure preservation rate defined as both skull base and orbit being preserved at 5 years and Overall survival at 5 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
docetaxelCisplatin micelle injection (HA132)carboplatin
03
Conditions
sinonasal squamous cell carcinoma (SNSCC)
Beyond the preview
Go deeper on NCT03493425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493425.